Transcript Faculty Eric Daar, M.D. Key Research From IDSA 2007: The 45th Annual Meeting of the Infectious Diseases Society of America San Diego, California | October.

Faculty
Eric Daar, M.D.
Key Research From IDSA 2007:
The 45th Annual Meeting of the Infectious Diseases
Society of America
San Diego, California | October 4-7, 2007
This activity is supported by an educational grant from
IDSA 2007: Faculty for This Activity
The Body PRO
Eric Daar, M.D.
Dr. Daar is the chief of HIV medicine at Harbor-UCLA Medical Center in Los
Angeles, Calif., and a professor of medicine at the University of California-Los
Angeles' David Geffen School of Medicine. He has been an active HIV
physician and researcher since the 1980s; during the past three decades, he
has led dozens of studies on a vast range of HIV-related issues, with a
particular focus on coinfections and other health complications associated with
HIV and HIV treatment, including hepatitis C, metabolic complications,
cardiovascular disease and psychosocial issues such as depression.
The Body PRO Covers IDSA 2007
IDSA 2007: Key Research
The Body PRO
About This Presentation
• This presentation was created to accompany The Body PRO's podcast
summary of key research presented at IDSA 2007, featuring an
interview with Eric Daar, M.D. For more information about this program,
please visit us on the Web at: TheBodyPRO.com/IDSA2007
• Please feel free to use this slide presentation for personal reference or
for your own presentations; however, we ask that you not modify any
aspects of the slides contained within this presentation so proper
attribution can be retained. If you would like to publish all or part of this
presentation, or repost any of these slides online, you must first obtain
permission from Body Health Resources Corporation.
• Our gratitude goes out to all who granted permission for their slides to
be adapted for this presentation.
Disclaimer
Knowledge about HIV changes rapidly. Note the date of this presentation's publication, and before treating patients or
employing any therapies described in these materials, verify all information independently. If you are a patient, please
consult a doctor or other medical professional before acting on any of the information presented in this presentation.
The Body PRO Covers IDSA 2007
The Body PRO
Challenges of Current Antiretroviral Therapy
The Body PRO Covers IDSA 2007
Immune Discordance While on HAART:
Methods
The Body PRO
Retrospective cohort study of patients initiated on HAART between January 1996 and July 2006.
Inclusion criteria
HIV-1 infection, age ≥ 18 years, baseline CD4+ T cells <350 cells/mm3 and viral suppression for ≥ 52 weeks.
Definitions
Discordant and concordant responders defined by CD4+ T cell gains of <150 or ≥ 150 cells/mm3 from HAART
initiation through 52 weeks of viral suppression and followed to death, virologic failure (lack of re-suppression of
viremia) or study termination.
Data collection
Socio-demographics, clinical, medication and laboratory data.
Sample collection and analysis
Blood samples from immune discordant and concordant responders (total n=45) with sustained viral suppression,
were obtained to determine the percentage of CD4+ and CD8+ T lymphocytes that were memory (CD45RO+) or
activated (CD38+,HLADR+), using three-color flow-cytometric analysis on cryopreserved peripheral mononuclear
cells.
Statistics
Data analyzed using SPSS version 14.0. Continuous variables compared using the Student’s t-test or MannWhitney U test. Chi square or Fisher’s exact tests used for categorical variables.
All p values were two-tailed and significant at <0.05 and potential predictive factors for immune discordance were
evaluated using multivariate logistic regression analyses.
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
Immune Discordance While on HAART:
Absolute CD4+ T Cell Counts After
HAART Initiation
600
Discordant
CD4+ (cells/mm)
500
Concordant
400
300
200
100
0
Baseline
VS
6
12
18
Months after HAART initiation
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
24
Immune Discordance While on HAART:
Results
The Body PRO
Discordant
(n=106)
Concordant
(n=192)
OR (95% CI)
P value
Male gender
89 (84%)
134 (70%)
2.27(1.24-4.15)
0.01
Age, (years)a
41.2 ± 0.9
38.2 ± 0.7
-
0.01
Caucasian
58 (55%)
75 (39%)
1.88(1.80-3.05)
0.01
African American
38 (36%)
108 (56%)
-
-
Men who have sex with men
56 (53%)
79 (41%)
1.78(1.08-2.93)
0.02
Heterosexual
30 (28%)
96 (50%)
-
-
Years since HIV diagnosisa
9.8 ± 0.5
8.3 ± 0.3
-
0.01
Previous OI
60 (57%)
104 (54%)
1.11(0.69-1.78)
0.72
Prior ARV experience
34 (32%)
62 (32%)
1.01(0.61-1.68)
1.00
CD4+ T cell nadir b
85 (21-180)
54(12-189)
-
0.43
Highest HIV RNA viral loada
4.90 ± 0.06
5.11 ± 0.07
-
0.05
Chronic Hepatitis C
17 (11%)
16 (8%)
1.97(0.96-4.04)
0.09
Chronic Hepatitis B
9 (6%)
21 (11%)
0.72(0.32-1.62)
0.55
Characteristics
Mode of transmission
±standard error of mean
(interquartile range), ARV = antiretroviral, NNRTI = non-nucleoside reverse transcriptase inhibitor,
NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor.
aMean
bMedian
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
Immune Discordance While on HAART:
Results
The Body PRO
Discordant
(n=106)
Concordant
(n=192)
OR (95% CI)
P value
126 (37-231)
88 (19-222)
-
0.15
4.68 ± 0.86
4.81 ± 0.06
-
0.19
NNRTI/ ≥ 2 NRTI
45 (42%)
92 (48%)
0.86(0.52-1.42)
0.61
All PI/ ≥ 2 NRTI
58 (55%)
87 (45%)
-
-
Unboosted indinavir
27 (26%)
24 (13%)
0.52(0.24-1.13)
0.01
No. (%) with HAART-related
side-effects
36 (34%)
35 (18%)
1.80(1.09-2.96)
<0.001
Weeks to viral suppression b
12 (6-23)
16 (8-28)
-
0.04
99 (50-133)
269 (211-374)
-
<0.001
Characteristics
At suppressive HAART initiation
CD4+ T cell count b
HIV RNA level
a
HAART regimen type
One year CD4+ T cell gain b
±standard error of mean
(interquartile range), ARV = antiretroviral, NNRTI = non-nucleoside reverse transcriptase inhibitor,
NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor.
aMean
bMedian
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
Immune Discordance While on HAART:
Independent Factors Associated With Immune
Discordance on Multivariable Analyses
• Male Gender
• Lower pre-HAART HIV-RNA viral load
• Any use of unboosted indinavir
• Greater number of HAART-related side effects per person
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
Immune Discordance While on HAART:
Clinical Outcomes During Long-Term
Follow-Up
Clinical Outcomes
Discordant Concordant (192) OR (95% CI)
P value
(106)
Years of viral suppression on HAARTa
4.56 ± 0.2
4.51 ± 0.2
-
0.88
392 (256-566)
682 (479-879)
-
<0.001
5 (5%)
9 (5%)
1.00 (0.33-3.09)
1.00
Remains in clinical care
75 (71%)
150 (78%)
-
Lost to follow up
26 (25%)
33 (17%)
-
1
1
-
-
Type of opportunistic illness
NHL
Kaposi’s sarcoma
-
-
Years after viral suppression
2 and 5
8
-
-
at 1 yr viral suppression
61 (58%)
73 (38%)
2.21 (1.36-3.58)
<0.001
at highest CD4+ T cell count
37 (35%)
30 (16%)
2.90 (1.66-5.01)
<0.001
Recurrent genital warts
5 (5%)
1 (1%)
9.46 (1.09-82.0)
0.02
Recurrent shingles
10 (9%)
7 (4%)
2.75 (1.02-7.46)
0.06
0
6 (3%)
1.57 (1.44-1.71)
0.09
Highest CD4+ T cell count attainedb
Death
New opportunistic illness
OI prophylaxis
Recurrent genital herpes
aMean
± standard error of mean, bMedian and interquartile range. NHL = non-Hodgkin’s lymphoma, OI = opportunistic infection.
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
Immune Discordance While on HAART:
Comparison of Activation and Memory T Cells
Between Discordant vs. Concordant Immune
Responders
Data at the time of FACS
analysis (mean ± S.E.M.)
Discordant
(n=20)
Concordant
(n=25)
P value
Age
Gender: Male
Female
Race: Caucasian/Hispanic
African American
48.7 ± 2.5
17 (85%)
3 (15%)
15 (75%)
5 (25%)
48.7 ± 1.9
19 (76%)
6 (24%)
10 (40%)
15 (60%)
0.86
0.71
CD4+ T cell count (cells/mm3)
% <200 cells/mm3
% 201-349 cells/mm3
% ≥ 350 cells/mm3
306 ± 30
20
50
30
683 ± 49
0
0
100
<0.001
Years of viral suppression
5.6 ± 0.5
7.0 ± 0.4
0.03
CD4+ T cellsa
CD45RO+
Naïve:memory
CD38+HLADR+
55.0 ± 3.6
1.1 ± 0.3
2.9 ± 0.4
45.1 ± 3.1
1.7 ± 0.3
2.0 ± 0.2
0.04
0.04
0.08
CD8+ T cellsa
CD45RO+
Naïve:memory
CD38+HLADR+
20.5 ± 2.7
5.2 ± 0.6
1.0 ± 0.2
17.6 ± 1.8
6.4 ± 0.8
1.1 ± 0.1
0.47
0.47
0.38
a
0.03
Percentage of total events. CD38+HLADR+ = marker of activation, CD45RO+ = marker of memory cell.
Nur F. Önen et al. IDSA 2007; abstract 952. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
LPV/r Switch for Patients With Suboptimal
Immune Responses to HAART Despite RNA
Suppression: Study Design
David Pitrak et al. IDSA 2007; abstract 955. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
Mean Increase in CD4 Count After a
Switch to Lopinavir/Ritonavir vs.
Continuation of HAART
Baseline=177
%Δ=68.5
Baseline=264
%Δ=19.1
Lopinavir/Ritonavir (N=8)
Continuation (N=9)
Adapted from David Pitrak et al. IDSA 2007; abstract 955.
The Body PRO Covers IDSA 2007
The Body PRO
Mean Apoptosis (Percent) of CD4CD45 RA+
(Naïve) T Cells After Switch to Lopinavir/Ritonavir
vs. Continuation of Current Regimen
Lopinavir/Ritonavir (N=8)
Continuation (N=9)
HIV-Negative Controls
(N=10)
Complete Responders
(N=10)
Adapted from David Pitrak et al. IDSA 2007; abstract 955.
The Body PRO Covers IDSA 2007
The Body PRO
Mean Apoptosis (Percent) of CD4CD45 RO+
(Memory) T Cells After Switch to Lopinavir/Ritonavir
vs. Continuation of Current Regimen
Lopinavir/Ritonavir (N=8)
Continuation (N=9)
HIV-Controls
Complete Responders
Adapted from David Pitrak et al. IDSA 2007; abstract 955.
The Body PRO Covers IDSA 2007
The Body PRO
LPV/r Switch for Patients With Suboptimal
Immune Responses to HAART Despite RNA
Suppression: Mean Change in CD4 Count
Beyond 24 Months
Lopinavir/Ritonavir (N=8)
Continuation (N=9)
Continuation Obs* (N=7)
Adapted from David Pitrak et al. IDSA 2007; abstract 955.
The Body PRO Covers IDSA 2007
Cross Allergy Between NNRTIs:
Patient Distribution
The Body PRO
Claudia P. Cortes et al. IDSA 2007; abstract 959. Reprinted with permission.
The Body PRO Covers IDSA 2007
Cross Allergy Between NNRTIs:
Results
The Body PRO
 1547 patients were treated with efavirenz (Sustiva, Stocrin) and 946 with nevirapine
(Viramune).
• 967 of these treatments required change of therapy.
• 554 (57.2%) of them, due to drug toxicity and 74 due to allergy.
 35 patients with allergy to nevirapine switched to efavirenz.
• 2/35 (5.7%) developed rash within 30 days. This was not significantly different from
4.6% of primary allergy to efavirenz in the Chilean AIDS Cohort population.
•31/33 (93%) of those without secondary allergy obtained viral suppression for at
least 15 months.
 Seven patients with efavirenz-induced rash underwent change to nevirapine.
• 2/7 (28.5%) developed rash.
• All remaining 5 patients obtained viral suppression for at least 15 months.
Claudia P. Cortes et al. IDSA 2007; abstract 959. Reprinted with permission.
The Body PRO Covers IDSA 2007
LPV/r Switch – Soft Gel Capsule to
Tablet: Methods
The Body PRO
This was a prospective cohort study that enrolled clinically stable HIV-infected
subjects receiving LPV/r-based antiretroviral regimen.
Screening
Laboratory Evaluations
• HIV-subjects age >18 years.
• Enrolled prior to, or within eight weeks
of formulation switch.
• No CD4 cell count restriction.
• No pregnancy/breastfeeding.
• Clinical labs monitored at baseline and
at week 12:
• Fasting lipid profile.
• HIV-1 RNA.
• CD4 cell count.
Bowel Movement Evaluation
Daily bowel habit (BH) was assessed prior to switch and at weeks 4 & 12. The bowel
habit score was assessed using the scoring system below and dividing the sum by 4.
Stool consistency:
solid =1, loose =3, watery=5
Volume:
small =1, moderate=3, large=5
Presence of blood in
stools:
no=1, yes=5
Frequency per day:
1 – 5 (>4 BM per day scored as 5)
The scale has a minimum of 1 (best BHS outcome) and a maximum of 5 (worst BHS
outcome).
Ighovwerha Ofotokun et al. IDSA 2007; abstract 962. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
LPV/r Switch – Soft Gel Capsule to
Tablet: Subject Demographic Data at
Study Entry
Study population (n = 74)
Male sex [n (%)]
61 (82)
Race
• African American [n (%)]
• White [n (%)]
• Hispanic [n (%)]
55 (74)
17 (23)
2 (3)
†On LPV/r tablet at entry
• No [n (%)]
• Yes [n (%)]
49 (66)
25 (34)
On anti-diarrheal drug
• No [n (%)]
• Yes [n (%)]
67 (92)
6 (8)
On lipid lowering drug
• No [n (%)]
• Yes [n (%)]
54 (74)
19 (26)
Median age [years (IQR)]
43 (39-47)
Median weight [kg (IQR)]
80.5 (69.6-88.6)
Median HIV-1 RNA [copies/ml (IQR)]
135 (50-170)
Median CD4 T-cell counts [cell/μl (IQR)]
294 (157-455)
LPV/r = lopinavir/ritonavir
SGC = soft gel capsule
IQR = inter quartile range
† Subjects were already
switched from LPV/r SGC to
tablets within eight weeks
prior to enrollment;
75% percentile,
25th to 75th percentile.
Ighovwerha Ofotokun et al. IDSA 2007; abstract 962. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
LPV/r Switch – Soft Gel Capsule to
Tablet: Change in Self-Reported
Bowel Habit
Bowel habit (BH) score*
Baseline to Week 4
(n= 70)
Overall change, mean ± SD
-0.281 ± 0.719
Bowel habit improvements among those reporting
a change
0.0017
Baseline to Week 12
(n=62)
-0.227 ± 0.707
Baseline to Week 4
0.0141
Baseline to Week 12
Improvement rate
P-value
Improvement rate
P-value
Decrease in stool frequency among those reporting
change
18/28 (64%)
0.13
18/32 (56%)
0.48
Improved stool consistency among those reporting
change
23/30 (77%)
0.0035
19/27 (70%)
0.0343
Decrease in stool volume among those reporting
change
11/16 (69%)
0.13
8/13 (62%)
0.41
5/6 (83%)
0.10
4/6 (67%)
0.41
Resolution of blood in stool among those reporting
change
SD = standard deviation
*BHS example, a subject with baseline responses of: solid, moderate, no blood in stool, and frequency of “2” would have a score of:
(1 + 3 + 1 + 2)/4 = 1.75 for their baseline summary score.
Ighovwerha Ofotokun et al. IDSA 2007; abstract 962. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
LPV/r Switch – Soft Gel Capsule to
Tablet: Changes in Fasting Lipid
Profile From Baseline to Week 12
Lipid Lowering Drug
Baseline
mean (SD)
Week 12
mean
(SD)
Mean change
(SD)
P-value
TC
No (n =38)
Yes (n=16)
Total population (n=54)
188 (35.1)
221 (66.2)
198 (48.4)
179 (34.7)
218 (55.8)
190 (45.3)
-9.20 (23.20)
-2.94 (44.30)
-7.33 (30.70)
0.0197*
0.795
0.0848
TRIG
No (n=33)
Yes (n=14)
Total population (n=47)
187 (117)
410 (410)
254 (260)
154 (111)
329 (304)
206 (203)
-33.10 (86.30)
-81.20 (348.30)
-47.40 (199.90)
0.035*
0.399
0.1108
HDL-C
No (n=33)
Yes (n=14)
Total population (n=47)
47.0 (11.3)
35.1 (15.9)
43.2 (14.0)
42.6 (11.9)
36.8 (15.8)
40.7 (13.4)
-4.50 (9.40)
1.70 (9.50)
-2.49 (9.78)
0.012*
0.490
0.877
LDL-C
No (n=33)
Yes (n=14)
Total population (n=47)
106 (29.4)
123 (54.5)
111 (38.8)
102 (24.4)
127 (32.3)
110 (29.0)
-4.20 (21.80)
3.60 (48.60)
-1.85 (31.80)
0.283
0.788
0.692
TC = total cholesterol; TRIG = triglyceride; HDL-C = high density lipoprotein; LDL-C = low density lipoprotein;
SD = standard deviation
*Statistically significant (P ≤ 0.05).
Ighovwerha Ofotokun et al. IDSA 2007; abstract 962. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
New Antiretroviral Options:
Emerging Data From Recently Approved Agents or
Agents Available in Expanded Access
The Body PRO Covers IDSA 2007
TITAN: Study Design
The Body PRO
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
TITAN: Virologic Response Through
Week 48 (ITT-TLOVR) – All Patients
The Body PRO
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
TITAN: Difference in Virologic
Response (VL <50 Copies/mL) at
Week 48: Univariate Analysis
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
TITAN: Baseline Characteristics
The Body PRO
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
TITAN: NRTIs and NNRTIs Used in
the Optimized Background Regimen
The Body PRO
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
TITAN: Impact of IAS-USA Primary PI
Mutations* at Baseline on VL <50
Copies/mL at Week 48
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
TITAN: Difference in Virologic Response
(VL <50 Copies/mL, ITT-TLOVR):
Multivariate Analyses
W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.
The Body PRO Covers IDSA 2007
Summary of Virologic Responses
Without (-) and With (+) Enfuvirtide (ENF)
The Body PRO
Adapted from Jacob P. Lalezari et al. IDSA 2007; abstract 964.
The Body PRO Covers IDSA 2007
The Body PRO
DUET 24-Week Efficacy: Patients With
Viral Load <50 Copies/mL at Week 24
(Primary Endpoint; ITT-TLOVR)
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
DUET 24-Week Efficacy: Mean Viral Load
Reduction From Baseline (ITT NC=F)
The Body PRO
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
DUET 24-Week Efficacy: CD4 Cell Count
Increase to 50 Cells/mm3 or Above
The Body PRO
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
DUET 24-Week Efficacy: Response
(<50 Copies/mL) According to Number
of Active Background Antiretrovirals
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
DUET 24-Week Efficacy: Response (<50
Copies/mL) According to Baseline Viral
Load and CD4 Cell Count
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
DUET 24-Week Efficacy: Mutations
Associated With a Decreased
Response to TMC125
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
DUET 24-Week Efficacy: Response
(<50 Copies/mL) According to Number
of TMC125 RAMS
Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.
The Body PRO Covers IDSA 2007
DUET 24-Week Safety: Overview of
Adverse Events
The Body PRO
Parameter, %
Any AE (any cause)
Grade 3 AE
Grade 4 AE
Serious AE (SAE)
Death (any cause)
Discontinuation due to AE
TMC125 group
(n=599)
Placebo group
(n=604)
92
22
7
13
1
6
93
25
9
19
2
4
Most common AEs (>10% in either group, regardless of severity and causality)*
Rash (any type)
17§
Diarrhea
15
Nausea
14
Headache
9
9
20
11
12
• AEs leading to death were not reported in more than one patient except for pneumonia and sepsis (n=2
each) in the placebo group
• None of the deaths in the TMC125 group were considered related to TMC125
*excluding injection site reactions; §p=0.0001 vs placebo; AE = adverse event
Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.
The Body PRO Covers IDSA 2007
DUET 24-Week Safety: Grade 3 and 4
Adverse Events
The Body PRO
AE regardless of causality, n (%)
Any grade 3/4 AE
TMC125 group
(n=599)
Placebo group
(n=604)
25
27
Most common grade 3/4 clinical AEs (>0.5% in pooled TMC125 group)*
Rash (any type)
1.3
0
Peripheral neuropathy
1.0
0
Pancreatitis
0.7
0
Pneumocystis jiroveci pneumonia
0.7
0.7
Renal failure
0.7
0.3
*excluding injection site reactions and grade 3/4 laboratory abnormalities reported as AEs
Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.
The Body PRO Covers IDSA 2007
DUET 24-Week Safety: Rash
The Body PRO
Investigator assessment of
cause of rash, %
Any cause
Possibly related to study medication
TMC125 group
(n=599)
Placebo group
(n=604)
17
12
9.4
4.8
Significance
p<0.001
• In the TMC125 group:
– Early onset: Median 12 days.
– Limited duration: Median 11 days.
– Low severity: Most mild to moderate; 1.3% grade 3, none grade 4.
• Mostly maculopapular; no mucosal involvement.
– Infrequently led to discontinuation: 2.2% of patients (0% with placebo).
• Most resolved with continued treatment.
• Clinical associations with rash
– No association with baseline CD4 cell count.
– No increased risk with prior NNRTI-related rash.
Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
DUET 24-Week Safety: Psychiatric
Disorders
•
Similar incidence to placebo: 13% in TMC125 group versus 15% in placebo group (p=0.3).
•
Low severity: mostly grade 1 and 2.
•
Infrequently lead to discontinuation: 1 patient (0.2%) in each group.
•
No increased risk in patients with a history of psychiatric disorders.
•
Abnormal dreams/nightmares in 5 patients (0.8%) in each group and no episodes of hallucinations,
suicidal ideation or manic symptoms with TMC125.
Patients experiencing psychiatric-related AEs, %
TMC125 group
(n=599)
Placebo group
(n=604)
0.2
1.3
0
0.2
6
7
3
5
3
3
1
1
Grade 3
Grade 4
Most common (reported in ≥1.0% of patients in the TMC125 group)
Insomnia
Depression
Anxiety
Sleep disorder
Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.
The Body PRO Covers IDSA 2007
DUET 24-Week Safety: Lipid Changes
Over Time
The Body PRO
TMC125 group
Change from
baseline (mg/dL)
100
Placebo group
20
Low Density Lipoprotein Calculated
80
15
60
10
40
5
20
0
0
-5
0
8
16
24
32
40
48
Total Cholesterol/High Density Lipoprotein
40
20
0
-20
-40
-60
-80
-100
High Density Lipoprotein
0
8
16
24
32
40
48
Triglycerides
50
Change from
baseline (mg/dL)
0
-50
-100
-150
-200
0
8
16
24
32
40
48
0
8
Week
16
Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.
The Body PRO Covers IDSA 2007
24
Week
32
40
48
DUET 24-Week Safety: Hospitalizations
The Body PRO
TMC125 group
Placebo group
20
2000
1700
15
p=0.0031
11%
10
5
0
Cumulative days hospitalized
by 24 weeks
Patients hospitalized at least once
by 24 weeks (%)
16%
1500
1105
1000
500
0
Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
A4001029: Phase 2b Pilot Study
Evaluating the Safety of Maraviroc
in Patients With Non-R5 HIV-1
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
A4001029: Baseline Characteristics
The Body PRO
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
A4001029: Baseline Characteristics
– Primary Study Population
The Body PRO
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
The Body PRO
A4001029: Percentage of Patients
With Undetectable HIV-1 RNA Over
48 Weeks
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
A4001029: Mean Change From
Baseline in CD4+ Count
The Body PRO
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
A4001029: Summary of Week 48
Safety Results
The Body PRO
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
A4001029: Number of Category C Events
The Body PRO
J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.
The Body PRO Covers IDSA 2007
IDSA 2007: Key Research
The Body PRO
• Visit The Body PRO for comprehensive coverage of IDSA 2007.
This presentation was created to accompany The Body PRO's summary
of key research presented at IDSA 2007, by Eric Daar, M.D. Learn
more at: TheBodyPRO.com/IDSA2007
• In addition, be sure to browse through The Body PRO’s extensive
coverage of IDSA 2007, which includes:
– A full written summary with expert discussion and analyses of key
research.
– Downloadable MP3s: listen on your computer or download to your
MP3 player.
– Slides and in-depth data analyses.
• Visit TheBodyPRO.com/IDSA2007 today for a full listing of our
conference materials!
The Body PRO Covers IDSA 2007